Lung cancer is the world's leading cause of cancer death. Screening for lung cancer by low- dose computed tomography improves mortality. Various modalities exist for diagnosis and staging. Treatment is determined by subtype and stage of cancer; there are several personalized therapies that did not exist just a few years ago. Caring for the patient with lung cancer is a complex task. This review provides a broad outline of this disease, helping clinicians identify such patients and familiarizing them with lung cancer care options, so they are better equipped to guide their patients along this challenging journey.
In the current study firstly, we have studied the effect of Absogen on lung cancer cell line A549 with respect to apoptosis, mitochondrial potential disturbance, and Reactive oxygen species generation.
Measurement of apoptosis, mitochondrial potential and ROS generation is the
arc where one can analyze the anticancer properties of a given drug. In the case of Absogen it was observed that it was able to induce apoptosis in the lung cancer cell line A549. The mitochondrial damage and reactive oxygen species generation was very high due to Absogen which makes it a potent contender to be developed as an anticancer therapeutic agent and should be tested on advance lung cancer animal models. The efficacy of Absogen on lung cancer cell line was so significant that even at very low concentrations the effect was clearly visible.